YMAB vs. AVTE, APLT, ABUS, IGMS, KALV, VERV, ATXS, ALT, SIGA, and CMPS
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Aerovate Therapeutics (AVTE), Applied Therapeutics (APLT), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), KalVista Pharmaceuticals (KALV), Verve Therapeutics (VERV), Astria Therapeutics (ATXS), Altimmune (ALT), SIGA Technologies (SIGA), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Aerovate Therapeutics presently has a consensus target price of $47.00, indicating a potential upside of 128.49%. Y-mAbs Therapeutics has a consensus target price of $17.33, indicating a potential upside of 49.43%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aerovate Therapeutics is more favorable than Y-mAbs Therapeutics.
Aerovate Therapeutics has a net margin of 0.00% compared to Aerovate Therapeutics' net margin of -25.64%. Aerovate Therapeutics' return on equity of -21.40% beat Y-mAbs Therapeutics' return on equity.
Y-mAbs Therapeutics received 102 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. However, 65.38% of users gave Aerovate Therapeutics an outperform vote while only 60.71% of users gave Y-mAbs Therapeutics an outperform vote.
70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 19.3% of Aerovate Therapeutics shares are held by insiders. Comparatively, 21.5% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Y-mAbs Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aerovate Therapeutics had 16 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 25 mentions for Aerovate Therapeutics and 9 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 0.45 beat Aerovate Therapeutics' score of 0.36 indicating that Aerovate Therapeutics is being referred to more favorably in the media.
Aerovate Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Summary
Y-mAbs Therapeutics beats Aerovate Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
